| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V425644-1ml |
1ml |
现货  |
|
| 别名 | 维多弗迪莫斯 |
|---|---|
| 英文别名 | EX-A4148 | s7262 | (+/-) ethylnipecotate | 2,2'-Anhydro(1.beta.-D-arabinofuranosyl)uracil | NCGC00246751-01 | NCGC00345056-01 | 4SC-101 | 4sc-101;SC12267 | A866371 | BCP14555 | AC-32911 | Vidofludimus | 2-((3-Fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamo |
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | Vidofludimus |
| 生化机理 | Vidofludimus（SC12267，4SC-101）是一种口服活性强效二氢烟酸脱氢酶（DHODH）抑制剂，对人类 DHODH 的 IC50 值为 134 nM。Vidofludimus钙（IMU-838）被研究作为COVID-19的潜在治疗方案。第二阶段 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 二氢烟酸脱氢酶抑制剂 |
| 产品介绍 |
Vidofludimus (SC12267, 4SC-101) 是一种口服具有活性的，有效的dihydroorotate dehydrogenase (DHODH)抑制剂，对人DHODH的IC50为134 nM。Vidofludimus calcium (IMU-838)正作为COVID-19的潜在治疗选择研究中。Phase 2 Information Vidofludimus Vidofludimus (SC12267, 4SC-101) is an orally active and potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 134 nM for human DHODH. Vidofludimus calcium (IMU-838) is investigated as a potential treatment option for COVID-19. Phase 2. Targets Human DHODH 134 nM In vitro Vidofludimus causes a concentration dependent inhibition of phytohemagglutinin-stimulated PBMC proliferation via the inhibition of pyrimidine de novo synthesis. Vidofludimus attenuates IL-17 secretion from colonic strips by inhibition of STAT3 and NF-κB activation. In vivo In MRLlpr/lpr mice, Vidofludimus (300 mg/kg, p.o.) reduces systemic autoimmunity and improves Lupus Nephritis. In Rats, Vidofludimus (60 mg/kg, p.o.) effectively reduces macroscopic and histological pathology and the numbers of CD3+ T cells. In a rat model of renal transplantation, Vidofludimus (20 mg/kg, p.o.) prolongs survival, paralleled by amelioration of histologic signs of acute rejection. Cell Research(from reference) Cell lines：PBMCs Incubation Time：48 h |
| ALogP | 3.878 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 5 |
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IUPAC Name | 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid |
| INCHI | InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25) |
| InChi Key | XPRDUGXOWVXZLL-UHFFFAOYSA-N |
| Canonical SMILES | COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F |
| Isomeric SMILES | COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F |
| PubChem CID | 9820008 |
| 分子量 | 355.36 |
| DMSO(mg / mL) Max Solubility | 100 |
|---|---|
| DMSO(mM) Max Solubility | 281.4047726 |
| Water(mg / mL) Max Solubility | ＜1 |
| 分子量 | 355.400 g/mol |
| XLogP3 | 3.400 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 355.122 Da |
| 单同位素质量Monoisotopic Mass | 355.122 Da |
| 拓扑极表面积Topological Polar Surface Area | 75.600 Ų |
| 重原子数Heavy Atom Count | 26 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 576.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08, GHS07 |
|---|---|
| 信号词 | Danger |
| 危险声明 |
H413: 可能对水生生物造成长期的有害影响 H302: 吞食有害 H360: 可能损害生育力或未出生的孩子 |
| 预防措施声明 |
P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P201: 使用前获取特殊说明 P308+P313: 如接触到或有疑虑：求医/就诊。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P202: 在阅读并理解所有安全预防措施之前，不要进行操作。 P330: 漱口 P301+P312: 如误吞咽：如感觉不适，呼叫急救中心/医生。 |
| Concentration(Compounding value) | 9.0-11.0(mmol/L) |
|---|---|
| Appearance(Colorless to light green liquid) | pass |
| Record the entire process by video | Conform |
| 1. Xiaoyu Gao, Kaifeng Guo, Shuangfeng Liu, Weixing Yang, Jun Sheng, Yang Tian, Lei Peng, Yan Zhao. (2024) A Potential Use of Vidarabine: Alleviation of Functional Constipation Through Modulation of the Adenosine A2A Receptor-MLC Signaling Pathway and the Gut Microbiota. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25 (23): (12810). [PMID:39684522] [10.3390/ijms252312810] |
| 1. Xiaoyu Gao, Kaifeng Guo, Shuangfeng Liu, Weixing Yang, Jun Sheng, Yang Tian, Lei Peng, Yan Zhao. (2024) A Potential Use of Vidarabine: Alleviation of Functional Constipation Through Modulation of the Adenosine A2A Receptor-MLC Signaling Pathway and the Gut Microbiota. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25 (23): (12810). [PMID:39684522] [10.3390/ijms252312810] |
首页
400-620-6333
